Interestingly, a recent study that employed the HuR small molecule inhibitor MS-444 revealed a critical role of HuR in the early onset of FAP but not in inflammatory bowel disease, thus, pointing to a cell-type specific impact of HuR on intestinal physiology and pathology [35]. Here, ELAVL1 is linked to inflammatory bowel disease.